TY - JOUR
T1 - A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation
AU - Llimos, Gerard
AU - Gardeux, Vincent
AU - Koch, Ute
AU - Kribelbauer, Judith F.
AU - Hafner, Antonina
AU - Alpern, Daniel
AU - Pezoldt, Joern
AU - Litovchenko, Maria
AU - Russeil, Julie
AU - Dainese, Riccardo
AU - Moia, Riccardo
AU - Mahmoud, Abdurraouf Mokhtar
AU - Rossi, Davide
AU - Gaidano, Gianluca
AU - Plass, Christoph
AU - Lutsik, Pavlo
AU - Gerhauser, Clarissa
AU - Waszak, Sebastian M.
AU - Boettiger, Alistair
AU - Radtke, Freddy
AU - Deplancke, Bart
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Non-coding variants coordinate transcription factor (TF) binding and chromatin mark enrichment changes over regions spanning >100 kb. These molecularly coordinated regions are named “variable chromatin modules” (VCMs), providing a conceptual framework of how regulatory variation might shape complex traits. To better understand the molecular mechanisms underlying VCM formation, here, we mechanistically dissect a VCM-modulating noncoding variant that is associated with reduced chronic lymphocytic leukemia (CLL) predisposition and disease progression. This common, germline variant constitutes a 5-bp indel that controls the activity of an AXIN2 gene-linked VCM by creating a MEF2 binding site, which, upon binding, activates a super-enhancer-like regulatory element. This triggers a large change in TF binding activity and chromatin state at an enhancer cluster spanning >150 kb, coinciding with subtle, long-range chromatin compaction and robust AXIN2 up-regulation. Our results support a model in which the indel acts as an AXIN2 VCM-activating TF nucleation event, which modulates CLL pathology.
AB - Non-coding variants coordinate transcription factor (TF) binding and chromatin mark enrichment changes over regions spanning >100 kb. These molecularly coordinated regions are named “variable chromatin modules” (VCMs), providing a conceptual framework of how regulatory variation might shape complex traits. To better understand the molecular mechanisms underlying VCM formation, here, we mechanistically dissect a VCM-modulating noncoding variant that is associated with reduced chronic lymphocytic leukemia (CLL) predisposition and disease progression. This common, germline variant constitutes a 5-bp indel that controls the activity of an AXIN2 gene-linked VCM by creating a MEF2 binding site, which, upon binding, activates a super-enhancer-like regulatory element. This triggers a large change in TF binding activity and chromatin state at an enhancer cluster spanning >150 kb, coinciding with subtle, long-range chromatin compaction and robust AXIN2 up-regulation. Our results support a model in which the indel acts as an AXIN2 VCM-activating TF nucleation event, which modulates CLL pathology.
UR - https://www.scopus.com/pages/publications/85128404746
U2 - 10.1038/s41467-022-29625-6
DO - 10.1038/s41467-022-29625-6
M3 - Article
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 2042
ER -